Wuhan Announces Opening Cape Town Office
CAPE TOWN, SA / ACCESSWIRE / March 22, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce today that the Company has signed a lease on a new office in Cape Town's trendy Woodstock area. The move will take place this week and will enable the company's divisions, including food sciences, cosmetics, hemp, aromatherapy to work more closely and cohesively under one roof.
"March 20, 2021, the Company committed to a lease for the new Company headquarters. This will no doubt create new opportunities as interaction and networking are key components in any successful business. The new facility is part of our business strategy at this critical period of economic turbulence. Throughout the challenges presented by the COVID-19 lockdown restrictions, the respective divisions continued to thrive and perform efficiently. We could not be more excited about getting our talented teams under one roof and let the magic happen, " said Jeff Robinson, CEO of Wuhan General Group.
"The entire team is equally excited to be able to further collaborate, and work together in person in an open-concept office. The new headquarters will permit increased team synergies and further strengthen our performance and proficiencies, " added Dr. Anna Morera Leralta, Wuhan CMO.
The Woodstock area is one of the most preferred creative-space addresses for technology and biotech businesses within Cape Town. It will help increase the company's ability to recruit more of the area's best talent.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".
For further information:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc.
View source version on accesswire.com: